Nasal septum perforation induced by bevacizumab therapy in patients with breast cancer

Bevacizumab is a recombinant monoclonal immunoglobulin G1 antibody that selectively binds to vascular endothelial growth factor (VEGF), thus preventing it from binding to the VEGF receptors, VEGFR-1 and VEGFR-2, which leads to the inhibition of angiogenesis.¹ Numerous landmark clinical trials have shown overall and/or progression-free survival benefit with bevacizumab-based chemotherapy regimens for patients with metastatic colorectal,^2,3 lung,⁴ breast,⁵ and renal cell⁶ carcinomas.

*For a PDF of the full article, click on the link to the left of this introduction.

Bevacizumab is a recombinant monoclonal immunoglobulin G1 antibody that selectively binds to vascular endothelial growth factor (VEGF), thus preventing it from binding to the VEGF receptors, VEGFR-1 and VEGFR-2, which leads to the inhibition of angiogenesis.¹ Numerous landmark clinical trials have shown overall and/or progression-free survival benefit with bevacizumab-based chemotherapy regimens for patients with metastatic colorectal,^2,3 lung,⁴ breast,⁵ and renal cell⁶ carcinomas.

*For a PDF of the full article, click on the link to the left of this introduction.

Bevacizumab is a recombinant monoclonal immunoglobulin G1 antibody that selectively binds to vascular endothelial growth factor (VEGF), thus preventing it from binding to the VEGF receptors, VEGFR-1 and VEGFR-2, which leads to the inhibition of angiogenesis.¹ Numerous landmark clinical trials have shown overall and/or progression-free survival benefit with bevacizumab-based chemotherapy regimens for patients with metastatic colorectal,^2,3 lung,⁴ breast,⁵ and renal cell⁶ carcinomas.

*For a PDF of the full article, click on the link to the left of this introduction.